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Abstract: Essential hypertension (EH) is a complex, polygenic condition with no single causative
agent. Despite advances in our understanding of the pathophysiology of EH, hypertension remains
one of the world’s leading public health problems. Furthermore, there is increasing evidence
that epigenetic modifications are as important as genetic predisposition in the development of
EH. Indeed, a complex and interactive genetic and environmental system exists to determine an
individual’s risk of EH. Epigenetics refers to all heritable changes to the regulation of gene expression
as well as chromatin remodelling, without involvement of nucleotide sequence changes. Epigenetic
modification is recognized as an essential process in biology, but is now being investigated for
its role in the development of specific pathologic conditions, including EH. Epigenetic research
will provide insights into the pathogenesis of blood pressure regulation that cannot be explained
by classic Mendelian inheritance. This review concentrates on epigenetic modifications to DNA
structure, including the influence of non-coding RNAs on hypertension development.
Keywords: essential hypertension; epigenetics; DNA methylation; histone modifications; non-coding
RNA; microRNAs
1. Introduction
Hypertension (HT) affects more than 1 billion people globally and is a major risk factor for stroke,
chronic kidney disease, and myocardial infarction [1]. Despite advances in our understanding of the
pathophysiology of HT and the implementation of more effective treatment and prevention strategies,
HT remains one of the world’s great public health problems [2]. The public health impact created by
HT is due to its contribution to cardiovascular disease (CVD) events, such as heart attack, congestive
heart failure, peripheral vascular disease, and stroke [3]. Essential hypertension (EH) is a complex,
polygenic condition with no single causative agent. Furthermore, there is increasing evidence that
epigenetic modifications are as important as genetic predisposition in the development of EH. Indeed,
a complex and interactive genetic and environmental system exists to determine an individual’s risk
of EH (Figure 1).
Epigenetic modification is recognised as essential in biological processes and in recent years there
has been studies investigating its role in the development of specific pathologic conditions. Research
into epigenetic mechanisms will provide insights into the pathogenesis of blood pressure regulation
that cannot be explained by classic Mendelian inheritance. Previous reviews in this field report on
the various epigenetic mechanisms impacting CVD [4–6] or they discuss a selection of epigenetic
modifications in the context of HT but exclude some recent, important findings, such as the influence
of long non-coding RNAs on HT [7–10]. This review concentrates on epigenetic modifications to DNA
structure, including the influence of non-coding RNAs on EH development.
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Figure 1. Influences on phenotype manifestation. Development of polygenic conditions, such as 
essential hypertension (EH), depend on a complex but interactive genetic and environmental system. 
2. Epigenetics 
Epigenetics refers to all heritable changes to the regulation of gene activity, without changes to 
the DNA sequence itself [11]. In other words, “epigenetics” refers to analysis of the human genome 
from the perspective of chromatin and chromosomes, as well as to the quintessential issue of  
the DNA sequence. Epigenetic modifications can be provoked by a variety of factors, including 
environmental influences during foetal and childhood development, chemical exposure, aging, 
dietary habits, and the use of recreational drugs and some prescription medications [10]. 
The launch of international initiatives, the Human Epigenome Project [12], which first released 
data in 2003, and the International Human Epigenome Consortium [13] formed in 2010, attest to the 
rapid expansion of interest in epigenetics. Epigenetic inheritance is an essential mechanism that 
enables the stable propagation of gene activity states from one generation of cells to the next [14];  
it is helping to resolve puzzling aspects of heredity, while explaining how the same genome can give 
rise to apparently contrasting phenotypic traits [15]. Chromatin consists of nucleosomes: DNA strands 
wrapped around histones. Several distinct biochemical processes can epigenetically modify both DNA 
and histones [10]. These include DNA methylation (Figure 2), post-translational histone modifications 
(Figure 3), and RNA-based mechanisms mediated by small non-coding microRNAs [16] (Figure 4). 
 
Figure 2. Epigenetic DNA methylation. DNA methylation involves the binding of a methyl group to 
the 5’ carbon of cytosine ring. This primarily occurs at CpG islands and results in inhibition of gene 
transcription, particularly if it occurs in the gene promoter region. It may also promote transcription 
if it is located at gene exons sites. DNA methylation is an essential biological process which is linked 
with several epigenetic phenomena including X-chromosome inactivation, genomic imprinting and 
repetitive element repression. 
Figure 1. Influences on phenotype manifestation. Development of polygenic conditions, such as
essential hypertension (EH), depend on a complex but interactive genetic and environmental system.
2. Epigenetics
Epigenetics r fers o all heritable changes to th regulation of gene activity, without changes to
the DNA sequence itself [11]. In other words, “epigenetics” refers to analysis of the human genome
from the perspective of chromatin and chromosomes, as well as to the quintessential issue of the DNA
sequence. Epigenetic modifications can be provoked by a variety of factors, including environmental
influences during foetal and childhood development, chemical exposure, aging, dietary habits, and
the use of recreational drugs and some prescription medications [10].
The launch of international initiatives, the Human Epigenome Project [12], which first released
data in 2003, and the International Human Epigenome Consortium [13] formed in 2010, attest to
the rapid xpansion f interest in epigenetics. Epigenetic inheritance is an essential chanism that
enable the stabl propagatio of gene activity states fro one generatio of cells to the next [14]; it is
helping to resolve puzzli g aspects of heredity, while explaining how the same genome can give rise
to apparently contrasting phenotypic traits [15]. Chromatin consists of nucleosomes: DNA strands
wrapped around histones. Several distinct biochemical processes can epigenetically modify both DNA
and histones [10]. These include DNA methylation (Figure 2), post-translational histone modifications
(Figure 3), and RNA-based mechanisms mediated by small non-coding microRNAs [16] (Figure 4).
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Figure 2. Epigenetic DNA methylation. DNA methylation involves the binding of a methyl group to
the 5’ carbon of cytosine ring. This primarily occurs at CpG islands and results in inhibition of gene
transcription, particularly if it occurs in the gene promoter region. It may also promote transcription if
it is located at gene exons sites. DNA methylation is an essential biological process which is linked
with several epigenetic phenomena including X-chromosome inactivation, genomic imprinting and
repetitive element repression.
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Figure 3. Histone modification. Post-translational changes in the form of histone modifications 
influence gene expression by controlling chromatin dynamics. Methylation is commonly associated 
with gene silencing and can directly interfere with the binding of transcription factors. Histone tail 
acetylation can increase the access of transcription factors to DNA by transforming condensed 
chromatin into a more relaxed structure. 
 
Figure 4. MicroRNA biogenesis. MiRNA biogenesis involves down-regulation of gene transcription via 
target mRNA degradation or by mRNA translation blockage. RISC: RNA-induced silencing complex. 
3. DNA Methylation 
Epigenetic DNA modification (methylation) occurs when a methyl group derived from  
S-adenosyl-L-methionine is bound to position 5 of the cytosine ring, forming 5-methyl-cytosine  
(5mC) [17] (Figure 2). This happens at specific dinucleotide sites called CpGs, as these are prone to 
such modifications [10]. CpG islands are short sequences of DNA with a high linear frequency of  
5’-CpG-3’ sequences. The “P” denotes the phosphoesteric bond linking the cytosine and the guanine 
nucleotides [9]. CpG islands are often located in the promoter regions and approximately 40% of 
genes contain CpG islands in the end 5’ region (promoter, untranslated region, and exon1). The rest 
of the genome (intergenic and intronic regions) is considered CpG poor [17]. In healthy somatic cells, 
up to 90% of CpG dinucleotide sites are methylated, except for those located in the promoter region, 
Figure 3. Histone m dification. Post-transl ti nal changes in the f rm f histone modifications
influence gene expression by controlling chromatin dynamics. Methylation is commonly associated
with gene silencing and can directly interfere with the binding of transcription factors. Histone
tail acetylation can increase the access of transcription factors to DNA by transforming condensed
chromatin into a more relaxed structure.
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3. DNA Methylation
Epigenetic DNA modification (methylation) o curs when a methyl group derived from
S-adenosyl-L- eth onine is bound to position 5 of the cytosine ring, forming 5-methyl-cytosine
(5mC) [17] (Figure 2). This happens at specific dinucleotide sites called CpGs, as these are prone to
such modificatio s [10]. CpG islands are short sequences of DNA with a high linear frequency of
5’-CpG-3’ sequences. The “P” denotes the phosphoesteric bond linking the cyt sin and the guanine
nucleotides [9]. CpG islands ar often located in th promote regions and approximately 40% of genes
contain CpG islands in the end 5’ region (promoter, untranslated region, and exon1). The rest of the
genome (intergenic and intronic regions) is considered CpG poor [17]. In healthy somatic cells, up to
90% of CpG dinucleotide sites are methylated, except for those located in the promoter region, which
appear to be somewhat protected from such modification [17]. Non-CpG island DNA methylation has
also been reported to influence protein-DNA interactions, gene expression and chromatin structure,
and stability [18] (Table 1). Functionally, DNA methylation suppresses gene transcription, so DNA
hypermethylation results in gene silencing [10].
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Different degrees of DNA methylation have been correlated with variable onset, timing, and
severity of EH (Table 1) [10,19]. Global genomic DNA methylation can be quantified by measuring the
amount of 5-methyl cytosine present in a DNA sample. Smolarek et al. [19] found a correlation between
decreased levels of 5mC in peripheral blood with an increase in EH grade severity. The concentration
of 5mC was calculated as a ratio of spot intensities and a significant deficit in 5mC was observed in
healthy controls, relative to levels found in the two severity grades of EH. The mean level of 5mC was
1.80 ˘ 0.69 in healthy controls and 1.14 ˘ 0.48 in all hypertensive subjects (specifically, 1.29 ˘ 0.50
grade 1, 0.99 ˘ 0.42 grade 2), indicating that global DNA methylation levels decrease as the severity of
EH increases. However in this study, the percentage of 5mC was expressed as a coefficient “R” value,
and the method for calculating “R” was not disclosed.
Table 1. Summary of methylation findings in relation to hypertension.
Reference Tissue Type/Sample Size Findings
Smolarek, et al. [19] Human: Peripheral blood; 60 with EH;30 controls
Mean 5mC amount in DNA significantly
decreased as HT severity increased.
Kato, et al. [20]
Human: Peripheral blood, cord blood,
muscle, liver, fat; 320,251 individuals
of East Asian, European and South
Asian ancestry
Multiple genetic variants involved with
vascular smooth muscle (IGFBP3, KCNK3,
PDE3A, PRDM6) and renal function
(ARHGAP24, OSR1, SLC22A7, TBX2)
discovered to be correlated with BP
modulation. Two-fold enrichment
discovered between DNA methylation
and sentinel blood pressure SNPs,
providing evidence for DNA methylation
role in blood pressure regulation.
Friso, et al. [21] Human: Peripheral blood; 25 with EH;32 with prednisone therapy
HSD11B2 gene promoter methylation
associated with EH onset via disruption
to THF/The ratio.
Goyal, et al. [22] Rat: Tissues: brain; 20 MLP pups, 17control pups
Hypomethylation of RAAS system genes
such as ACE resulting in HT in offspring.
Wang, et al. [23] Human: Peripheral blood; 8 EH;8 control
PRCP gene hypomethylated in EH, linked
to disruption in cleavage of angiotensin II
and III.
Pei, et al. [24] Rat: Tissue: aorta; 6 SpontaneouslyHT; 6 WKY control
Atgr1a gene progressively
hypomethylated as SHR age progressed.
Indicating increased expression of Atgr1a
in aging SHR.
Riviere, et al. [25] Rat: Cultured endothelial cellsfrom WKY
Hypermethylation associated with
trasciptional repression of sACE,
indicating a role for epigenetics in sACE
modulation during HT.
Lee, et al. [26] Rat: Tissues: aorta, heart; SHRand WKY
Hypomethylation of Sic2a2 gene lead to
increased expression of NKCC1 which
was positively correlated with HT.
EH: essential hypertension; MLP: maternal low protein; HT: Hypertension; SHR: spontaneously hypertensive
rat, WKY: Wistar Kyoto rat; 5mC: 5-methyl-cytosine; ACE: angiotensin converting enzyme; RAAS:
renin-angiotensin-aldosterone system; sACE: somatic ACE; SNPs: single nucleotide polymorphisms; NKCC1:
Na+-K+-2Cl´ cotransporter 1; BP: blood pressure.
The most robust data on the involvement of methylation in blood pressure regulation comes from
the study by Kato et al. [20]. Kato and colleagues performed a genome-wide association and replication
study and identified genetic variants at 12 new loci that correlated with blood pressure modulation in
320,251 individuals of East Asian, European, and South Asian ancestry [20]. An investigation of the
relationship between the sentinel blood pressure single nucleotide polymorphisms (SNPs) with local
DNA methylation in 1904 South Asians (peripheral blood; Illumina Human Methylation 450 Bead Chip
array (Erasmus Medical Centre, Rotterdam, The Netherlands)) revealed a two-fold enrichment between
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sequence variation and DNA methylation. Twenty-eight of the 35 sentinel SNPs were associated with
one or more methylation markers [20], suggesting that DNA methylation may lie on the regulatory
pathway linking sequence variation and blood pressure. Genes associated with the 12 newly identified
SNP loci include those involved with vascular smooth muscle (IGFBP3, KCNK3, PDE3A, PRDM6)
and renal function (ARHGAP24, OSR1, SLC22A7, TBX2) [20]. Investigation of cross-tissue patterns of
DNA methylation at the leading 26 CpG sites associated with the sentinel SNPs showed that DNA
methylation in the blood was closely correlated with methylation patterns of various tissues (liver,
muscle, subcutaneous and visceral fat). While these potentially ground-breaking results indicate that
methylation levels in blood may provide a proxy for methylation patterns in other tissues, further
research is needed to investigate this correlation with a hypertensive affector organ, such as the kidney.
Initial DNA methylation research centred on correlating EH with the global level of 5mC [19], but
more recent studies have focused on the methylation of specific DNA sequences. The hydroxysteroid
dehydrogenase-11β2 enzyme (HSD11B2) converts cortisol to cortisone, which is found in circulatory
concentrations up to 1000 times higher than aldosterone (the primary mineralocorticoid hormone
and sodium (Na) transport modulator of the renin-angiotensin-aldosterone system (RAAS)) [10].
Cortisol and aldosterone bind mineralocorticoid receptors with equal affinity, but due to the difference
in concentration of the hormones, cortisol has a larger role in sodium reabsorption by the kidneys
and, in consequence, plays a larger role in fluid-related arterial pressure [10]. HSD11B2-mediated
degradation of cortisol to cortisone is disrupted when the promoter region of the HSD11B2 gene is
hypermethylated [27,28]. The resulting imbalance in the active metabolites of cortisol and cortisone,
tetrahydrocortisol (THF), and tetrahydocortisone (THE), respectively, promotes the onset of HT [27,28],
in accord with the findings by Friso et al. [21]. Friso et al. [21] also found that HSD11B2 promoter
methylation was associated with EH, with parallel disruptions to the THF/THE ratio.
Due to the well-known involvement of the RAAS system on arterial pressure regulation, any
changes in the activation status of RAAS-regulated genes have a pronounced effect on an individual’s
potential to develop HT. This effect has been extensively tested in animal models of HT [29].
Hypomethylation of the promoter regions of the angiotensin II type 1b receptor gene in the adrenal
glands of the maternal low protein (MLP) rat promoted HT through an exaggerated response to
salt [29]. The same effect was seen in a second study, where maternal protein deficiency during
pregnancy induced hypomethylation of the promoter regions of RAAS-responsive genes, such as
angiotensin converting enzyme (ACE), causing predisposition to HT in offspring as well as cognitive
deficits [22]. The human PRCP gene encodes a lysosomal prolylcarbopeptidase protein, which is
implicated in cleavage of c-terminal amino acids linked to proline in peptides such as angiotensin II
and III [30]. Methylation profiling conducted on young African males revealed that the PRCP gene
was hypomethylated in EH subjects [23]. Similarly, when expression patterns of the angiotensin 1a
receptor (Atgr1a) were analysed in both spontaneously hypertensive rat (SHR) and its normotensive
control, the Wistar Kyoto rat (WKY), expression of Atgr1a was significantly increased by week 20 in
the SHR. Bisulfite sequencing revealed that the Atgr1a promoter from endothelial cells in the aorta
and mesenteric arteries of the SHR rats became progressively hypomethylated with age compared
to their WKY counterparts [24], suggesting heightened Atgr1a expression in the SHR was related to
the hypomethylation of the Atgr1a promoter and may have a role in the maintenance of high blood
pressure. Somatic ACE (sACE) converts angiotensin I to the active form, angiotensin II and is, therefore,
a key regulator of blood pressure [25]. Bisulfite sequencing conducted on cultured endothelial cells
and Wistar Kyoto rats revealed that hypermethylation was associated with transcriptional repression
of sACE, indicating possible epigenetic involvement of sACE modulation in HT [25].
Membrane transporters such as Na+-K+-2Cl´ cotransporter 1 (NKCC1), participate directly with
fluid and electrolyte loss and therefore arterial pressure regulation [26]. NKCC1, expressed by the
Sic2a2 gene, mediates the transport of sodium, potassium and chloride into and out of the cells [10].
Changes in ion fluxes have been implicated in EH, particularly an augmented, passive influx Na+,
K+, Rb+, and Cl´ in hypertensive vascular smooth muscle cells [26]. Hypomethylation of the Sic2a2
Int. J. Mol. Sci. 2016, 17, 451 6 of 14
gene promoter in the SHR aorta and heart, result in increased expression of NKCC1 and is positively
correlated with HT [26].
Methyl CpG binding protein 2 methylates the norepinephrine transporter gene, silencing
its expression [10]. Hypermethylation of the norepinephrine transporter gene, which transports
norepinephrine and dopamine from the synaptic gap back to the pre-synaptic neuron, has been shown
to lead to increased transport responsiveness, resulting in EH [31]. Furthermore, phenyl-ethanolamine
N-methyltransferase (PNMT), which can act similarly to methyl CpG binding protein 2, has been
shown to exacerbate the decrease in norepinephrine uptake, thereby enhancing the local and systemic
catecholaminergic effect [31].
4. Histone Modification and Hypertension
DNA is packaged into the dynamic protein structure of chromatin, whose basic unit is the
nucleosome. A nucleosome comprises of two copies each of the histone proteins H2A, H2B, H3, and
H4 [32]. Post-translational modifications regulate gene expression by controlling the dynamics of
chromatin. Modifications occurring at residues in histone tails include acetylation and methylation
(Figure 3) as well as phosphorylation, sumoylation, and biotinylation [32].
Epigenetic histone modification occurs when the N-terminal tail is subjected to a variety of
post-translational modifications [10]. Up to 60 possible modifications can occur. Specifically, the
nucleotide lysine can be modified by methylation, acetylation, ubiquitylation, or sumoylation,
whereas arginine can only be modified by methylation, and serine and threonine are modified
only by phosphorylation [10]. While each histone modification pattern has a unique impact on
the corresponding nucleosome, generally, the outcomes are similar: histone acetylation promotes
gene transcription while deacetylation represses transcription; histone lysine methylation in
position 79 inhibits while histone arginine methylation activates gene transcription; histone lysine
hypermethylation or mono-methylation at position 9 can have opposing effects—respectively silencing
or activating the target gene [9] (Table 2).
Table 2. Summary of histone modification findings in relation to hypertension.
Reference Tissue Type/Sample Size Findings
Han, et al. [33] Rat: Tissue: Aorta, renal artery;SHR and WKY
Up-regulated histone modifier H3K27me3
in renal artery of SHR correlated with HT
improvement after resveratrol intake.
Fish, et al. [34] Human: Umbilical veinendothelial cells
Endothelial cell nucleosomes
corresponding to eNOS enriched in
various histones relevant to eNOS
expression.
Lee, et al. [35]
Rat: Tissue: adrenal gland, aorta,
heart, kidney, liver, and lung. SHR
and WKY
Higher expression of Ace1 mRNA &
protein in SHR. Ace1 promoter enriched
with H3Ac and H3K4me3 in SHR.
Cho, et al. [36] Rat: Tissue: Mesenteric artery,aorta; SD and Sham rat.
Nkcc1 up-regulated in SD rat. Acetylated
histone H3 up-regulated, trimethylated
histone H3 down-regulated.
Duarte, et al. [37]
Human: Peripheral blood; First
sample: 206 mixed sex,
normotensive; Second sample: 730
mixed sex, HT and normotensive.
DOT1L strongly associated with increased
BP in Caucasians. Possibly via mediation
of hypermethylation of H3.
Mu, et al. [38]
Mouse: Tissue: Kidney;
norepinephrine infused-C57 BL/6j,
Adrb1 knockout and Adrb2
knockout mice.
WNK4 down-regulation caused increased
H3 & H4 acetylation, leading to
overexpression of NCC and therefore
promoting HT onset.
eNOS: endothelial nitric oxide synthase; SD: Sprague–Dawley rat; DOT1L: DOT1-like histone H3K79
methyltransferase; NCC: sodium chloride co-transporter; WNK4: with-no-lysine kinase 4.
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Histone modification affecting arterial pressure levels has been documented in a variety of human
and animal tissues, including vascular smooth muscle. Vascular oxidative stress can contribute to
endothelial dysfunction—a hallmark of HT—and the development of HT. A study by Bhatt et al. [39]
documented the beneficial effects of resveratrol on endothelial function in the SHR. A later study
of the mechanisms behind this effect was conducted by Han et al. [33]. Epigenetic modifications, in
the form of up-regulated H3K27me3 expression was observed in the renal artery of a salt-sensitive
hypertension model of the Wistar rat [33], possibly correlating with the improvement observed in HT
status but this was not clear. Endothelial nitric oxide synthase (eNOS) is primarily responsible for the
production of nitric oxide in the vascular endothelium, and plays a key role in the regulation of vascular
tone [33]. eNOS activity is thought to be down-regulated in CVD. Fish et al. [34] found that eNOS
expression appears to be controlled by cell-specific histone modifications. They also demonstrated that
the nucleosomes of endothelial cells corresponding to the eNOS core promoter were enriched in lysine
9 of histone H3 and lysine 12 acetylation of histone H4, and of di- and tri-methylation of lysine 4 of
histone H3. Fish et al. [34] observed that all of these epigenetic histone modifications were significantly
important for the expression of eNOS [34].
The study by Riviere et al. [25] noting the modulation of sACE by CpG methylation also
documented the involvement of histone deacetylases in the same process. Later findings of
Lee et al. [35] further validated these observations. Riviere et al. [25] also found that tissues from
SHRs exhibit higher expression levels of Ace1 mRNA and protein than those of WKY controls. They
found the Ace1 promoter regions of the SHR tissues were more enriched with H3Ac and H3K4me3,
and concluded that Ace1 is locally up-regulated in SHR tissues via histone code modifications [35].
In line with observations by Lee et al. [26], Cho et al. [36] found that levels of the membrane
transporter Nkcc1 mRNA and protein in the aortas of Sprague–Dawley (SD) rats were significantly
increased after administration of an angiotensin II infusion. Cho et al. [36] found that acetylated histone
H3 (an activating histone), was significantly increased together with greatly decreased trimethylated
histone H3 (a deactivating histone) [36], suggesting that both histone modification and/or DNA
demethylation have a role in the epigenetic up-regulation of Nkcc1 during HT development.
Disruptor of telomeric silencing-1 (DOT 1), a methyl-transferase, enhances methylation of lysine
79 residue of histone H3 (H3K79) [10]. DOT1-mediated hypermethylation of H3 disrupts silencing
of genes associated with maintaining telomere length during DNA repair, located in the telomeric
regions of chromosomes [40]. This disruption correlates with a decrease in connective tissue growth
factor transcription, increased intracellular cAMP and alterations in the adaption of blood vessels
to stressors—associated with HT [40]. In Caucasians, DOT1-like histone H3K79 methyltransferase
(DOT1L) is strongly associated with increased blood pressure in response to hydrochlorothiazide [37].
Activation of the renal sympathetic nervous system has long been thought to play a crucial
role in the development of salt-reactive HT [41]. Overactivity of renal sympathetic pathways can
promote the activation of several mechanisms which lead to increased sodium retention, including
stimulation of renin release, reduced renal blood flow, and increased sodium reabsorption in the
loop of Henle [42,43]. Serine-threonine kinases have a key role in renal tubular sodium reabsorption;
specifically, the with-no-lysine (WNK) family of serine-threonine kinases [44]. In normotensive mice,
a low-sodium diet decreases expression of renal WNK4, whereas a high sodium diet increases its
expression [45,46]. Renal sympathetic activity can also promote sodium reabsorption via activation of
the β-2 adrenergic receptor (β2AR) leading to cyclic AMP (cAMP) production, and increased activity of
renal epithelium sodium channels (ENaC) [30]. WNK4 signalling targets ENaC, and may also mediate
the prohypertensive effects of renal sympathetic overactivity. In addition to the classical cAMP pathway,
cAMP modulates gene transcription via inhibition histone deacetylase-8 activity leading to increased
histone acetylation [47,48]. Mu et al. [38] found that salt loading triggers β-adrenergic-mediated
down-regulation of renal WNK4, increases salt retention, and consequently leads to the development
of salt sensitive HT. WNK4 was recently found to be negatively regulated by the glucocorticoid
receptor [49]. Mu et al. [38] also noted that the underlying mechanism down-regulating renal WNK4 is
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cAMP dependent modulation of histone acetylation, which consequently increased histone H3 and
H4 acetylation. Acetylation of H3 and H4 seems to favour binding of the glucocorticoid receptor to
a WNK4 promoter region that contains a negative glucocorticoid-responsive element [38]. Mu et al.
found WNK4 expression was inhibited via these pathways leading to overexpression of the sodium
chloride co-transporter (NCC) and the onset of HT [38].
5. Non-Coding RNAs and Hypertension
Non-coding RNAs (ncRNA) are implicated in several epigenetic processes, notably small RNAs
that can influence histone modifications and cytosine methylation which are connected with gene
expression regulation [50]. NcRNA modification can produce effects analogous to classical DNA or
histone epigenetic mechanisms described earlier, or can induce HT via separate, distinct processes.
Essentially, epigenetics allow the same genome to show alternative phenotypes based on different
epigenetic influences. Some of the most complicated and researched epigenetic phenomena including
X-chromosome inactivation, parental imprinting and paramutation have an RNA contribution, either
directly or indirectly [50]. While most ncRNAs have no identified function yet, it is conceivable that
all are participants in epigenetic mechanisms which are yet to be clearly defined. NcRNAs have a
strong influence on the “central dogma” of biology. The past view that all DNA was transcribed
into RNA and then translated into protein has now been updated to include the fundamental role
of ncRNAs on the regulation protein levels. Recently, several small and mid-sized ncRNAs have
been described and are known to have a role in the regulation of transcription, post-transcription
and translation. Small ncRNAs include PIWI-interacting RNAs (piRNAs), transcription initiation
RNAs, and microRNAs (miRNAs) [8,51]. Mid-size ncRNAs include small nucleolar RNAs, promoter
upstream transcripts, TSS-associated RNAs, and promoter-associated small RNAs. Long ncRNAs
(lncRNAs) are most commonly associated with a reduction in transcription but may also have a role in
the regulation of miRNA levels [8]. For a comprehensive review of miRNAs and blood pressure refer
to the review paper by Marques et al. [51]. Here we will deliver a brief summary of some additional
key miRNAs involved in HT as well as a review of lncRNAs.
MiRNAs are the most commonly studied small ncRNA; currently there is no research available
investigating the involvement of the other types of small and mid-sized ncRNAs in EH. There are
more than 1800 miRNAs in the genome, each approximately 22 nucleotides in length [52]. miRNAs
down-regulate protein-coding genes by binding to target sequences in the 3’ (5’ targeting is uncommon
but possible) untranslated region of a target mRNA, resulting in mRNA degradation or repression of
mRNA translation [53] (Figure 4). Evidence suggests a single miRNA can regulate numerous mRNAs,
so it is plausible that miRNAs are causative agents for complex deletions [53]. miRNAs are increasingly
implicated as regulators of cardiovascular system [54], including modulation of arterial pressure [49]
(Table 3).
Table 3. Summary of non-coding RNAs in relation to hypertension.
Reference Tissue Type/Sample Size Findings
Goyal, et al. [22] Rat: Tissues: brain; 20 maternallow protein pups, 17 control pups
mmu-miR-27a and mmu-miR-27b
regulate ACE1 and was upregulated (3.3-
and 8.8-fold respectively) in MLP rat;
mmu-mir-330 regulates angiotensin II
type 2 receptor (AT2) and was
downregulated 3.5-fold in MLP rat.
Sethupathy, et al. [55] Human: Fibroblasts frommonozygotic twin; n = 2
Has-miR-155 binds to 3’UTR of AGR1
mRNA “A” allele causing a reduction in
AGTR1 mRNA, reducing the pressor
effect in response to angiotensin II.
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Table 3. Cont.
Reference Tissue Type/Sample Size Findings
Cheng, et al. [56] Human: Endothelial cells frompre-eclamptic placentas
Has-miR-155 up-regulated in
preeclampsia placentas, indicating
involvement in regulation of AGTR1.
Marques, et al. [57]
Human: Tissue: kidney; Sample 1:
42 mixed sex, Polish individuals of
mixed HT status; Sample 2: 22
male only, mixed HT status. All
samples untreated for HT
Has-miR-181a & has-miR-663 is able to
bind 3’UTR of renin mRNA, found to be
underexpressed in EH. These miRNA able
to regulate renin mRNA directly,
explaining overexpression of renin in
EH kidney.
Wang, et al. [58]
Mouse: Tissue: Mesenteric
arterioles; 16 male C57Bl/5 mice;
16 sham mouse control
siRNA targeting p22phox mRNA
demonstrated inhibition of contractile
response from angiotensin II,
consequently lowering BP.
Cabili, et al. [59] Human: Tissue: 24 various andcells lines; 24 human samples
lincRNAs may promote the transcription
of their neighbouring coding genes,
including those implicated in EH and
BP regulation.
Annilo, et al. [60]
Human and Mouse: Various
tissues and cell lines;
n = not disclosed
Seven blood pressure candidate genes
ADD3, NPPA, ATP1A1, NPR2, CYP17A1,
ACSM3 and SLC14A2 were connected
with cis-lncRNA transcripts.
In regards to the RAAS-regulated genes, it appears that miRNAs may also have a role modulating
ACE mRNA transcription [29]. MiRNA has-miR-155 was found by Sethupathy et al. [55] to target the
polymorphic sequence located in the 3’UTR of AGTR1 mRNA. This site has a Mendelian C (minor)
and an A (major) allele. The minor-C allele is associated with EH [55]. Has-miR-155 binds most
effectively to the A allele, leading to a reduction in AGTR1 mRNA in EH individuals who inherit
this allele. Individuals with the C allele did not have reduced AGTR1 mRNA and exhibited a greater
pressor effect in response to angiotensin II [55]. Has-miR-155 is also found to be up-regulated in
preeclampsia placentas; it regulates AGTR1 expression in umbilical vein endothelial cells [56]. A recent
genome-wide association study documented expression of mRNAs and miRNAs in kidneys from
untreated EH individuals, which were removed as a consequence of renal cancer [57]. Two miRNAs
(has-miR-181a and has-miR-663) with the ability to bind to the 3’UTR of renin mRNA were found
to be under-expressed in EH. These miRNAs were able to regulate the expression of a reporter gene
and renin-mRNA itself, which explains over-expression of renin mRNA seen in EH kidney [57].
In reference to DOT1 causing hypermethylation of H3 [37] (mentioned earlier), small interfering
RNAs (siRNA) have been shown to have an opposite effect by silencing the expression of the DOT1
gene [61]. Furthermore, siRNAs have been observed to have a role in modulating the RAAS system [61].
Angiotensin II was shown to induce a contractile response in smooth muscle cells extracted from mice
overexpressing p22phox, a subunit of NADPH oxidase responsible for activating NADPH oxidase and
generating superoxide anions in atherosclerotic plaques in human blood vessels [62]. siRNA targeting
p22phox inhibits the contractile response from angiotensin II, lowering blood pressure [58].
Long non-coding RNAs (lncRNAs), a heterogeneous group of non-coding transcripts longer
than 200 nucleotides, regulate their targets by influencing epigenetic control, mRNA processing,
translation or chromatin structure. LncRNAs have been implicated in several biological processes,
including transcriptional regulation by epigenetic mechanisms [63]. An exemplary representation is
X-chromosome inactivation present in the female genome of mammals which involves the inactivation
of one copy of a female sexual chromosome by DNA methylation. This process is coordinated by
the X-inactive specific transcript (XIST) and the XIST antisense transcript (TSIX) ncRNAs, very long
ncRNAs whose expression can be regulated by epigenetic mechanisms such as DNA methylation [50].
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Large intergenic non-coding RNAs (lincRNAs) have been identified both as modulators of health
development [64–66] and disease states [67], and may regulate the expression of neighbouring genes
and distant loci [63]. LincRNAs are more tissue specific than are protein-coding genes [59], suggesting
they have selective functions in different tissues. Cabili et al. [59] have described the annotation and
tissue-specific expression of all lincRNAs. Their gene ontology analyses were based on lincRNA
expression in different tissues [59]. The protein-coding genes located close to lincRNA loci included
genes previously associated with EH and blood pressure regulation, for example, those encoding
corticotropin-releasing hormone [59], suggesting many lincRNAs have an enhancer-like function
that promotes transcription of their neighbouring coding genes [68]. LncRNAs have a potential to
influence CVD, stroke, blood pressure and HT. Seven blood pressure candidate genes ADD3, NPPA,
ATP1A1, NPR2, CYP17A1, ACSM3, and SLC14A2 were connected with cis-lncRNA transcripts [60].
Of these, the lncRNA NPPA-AS was selected for further investigation which revealed NPPA-AS has a
demonstrated influence on the splicing of the natriuretic peptide precursor A (NPPA) gene (present in
cardiac hypertrophy and heart failure) and, therefore, has potential CVD involvement [60].
6. Conclusions
We are entering a new era of understanding how the genome interacts with the environment to
affect disease pathogenesis. There is now emerging evidence that epigenetic, as well as genetic, factors
are key players in regulating and maintaining blood pressure, and strong evidence for a complex
interaction of genetic and environmental factors that influence the risk of HT in each individual
(Figure 5). Many epigenetic studies are, however, limited by the fact that only blood is studied rather
than the effector tissues. The utility of blood methylation status in epigenetic research is yet to be
determined. Furthermore, the polygenic complexity of HT and the limited knowledge on some of the
non-coding RNAs makes it more challenging to decipher the exact mechanisms involved. Further
studies in humans and in animal models will be needed to elucidate the exact mechanisms involved
and to determine possible therapeutic applications.
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Figure 5. Impact of epigenetic modifications. DNA wrapped around nucleosomes are made up of 
four pairs of histone proteins. Histone proteins are prone to epigenetic modification, primarily 
acetylation and methylation but also phosphorylation, sumolyation, and biotinylation. These 
modifications change the formation of chromatin to either an open (active) or closed (inactive) state, 
thereby altering their transcriptional activity. DNA methylation changes the structure of DNA itself, 
allowing active transcription or silencing of genes. The outcome of DNA methylation is dependent 
on the location of the methylated site. miRNAs primarily target the 3’ UTR of mRNA (although 5’ 
targeting is possible). This negatively regulates the quantity of the encoded protein produced via 
degradation of mRNA molecules or by post-transcriptional regulation of mRNA stability. 
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Figure 5. Impact of epigenetic modifications. DNA wrapped around nucleosomes are made up of four
pairs of histone proteins. Histone proteins are prone to epigenetic modification, primarily acetylation
and methylation but also phospho ylation, sumolyation, and biotinylation. These modifications
change the formation of chromatin to either an open (active) or closed (inactive) state, thereby altering
their transcription l activity. DNA methylation changes the stru ture f DNA itself, allowing active
transcription or silencing of genes. The outcome of DNA methylation is dependent on the location of
the methylated site. miRNAs primarily target the 3’ UTR of mRNA (although 5’ target ng is possible).
This negatively regulates the quantity of the encoded protein produced via degradation of mRNA
molecules or by post-transcriptional regulation of mRNA stability.
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